AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says

uniQure anticipates that the U.S. Food and Drug Administration will likely convene an Advisory Committee meeting to evaluate its gene therapy candidate for Huntington’s disease. The company's chief medical officer indicated that such a meeting is expected given the novel nature of the treatment and the complexity of the condition. This development is a significant milestone for the pharmaceutical sector as it navigates the regulatory landscape for genetic interventions in neurodegenerative disorders.